In some patients with rheumatoid arthritis (RA), joint pain is more severe than expected based on the amount of joint swelling (referred to as disproportionate articular pain [DP]). We assessed DP prevalence and effects of sarilumab, an interleukin-6 inhibitor, on DP.
